Using imaging biomarkers to accelerate drug development and clinical trials
Authors:
- Homer H. PienHPHomer H. Pien
- Alan J. FischmanAFAlan J. Fischman
- James H. ThrallJTJames H. Thrall
- A.GRegory SorensenASA.GRegory Sorensen
- 1 February 2005
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 10 (4) , 259-266
Abstract
No abstract availableKeywords
This publication has 56 references indexed in Scilit:
- Role of surrogate markers in assessing patients with diabetes mellitus and the metabolic syndrome and in evaluating lipid-lowering therapyThe American Journal of Cardiology, 2004
- Positron emission tomography microdosing: a new concept with application in tracer and early clinical drug developmentEuropean Journal of Clinical Pharmacology, 2003
- Structural, Functional, and Molecular MR Imaging of the MicrovasculatureAnnual Review of Biomedical Engineering, 2003
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Clinical translation of angiogenesis inhibitorsNature Reviews Cancer, 2002
- Pharmacokinetic ImagingClinical Pharmacokinetics, 2002
- Scaling down imaging: molecular mapping of cancer in miceNature Reviews Cancer, 2002
- The Value of Improving the Productivity of the Drug Development ProcessPharmacoEconomics, 2002
- Usefulness of Magnetic Resonance–Derived Quantitative Measurements of Cerebral Blood Flow and Volume in Prediction of Infarct Growth in Hyperacute StrokeStroke, 2001
- In vivo diffusion–perfusion magnetic resonance imaging of acute cerebral ischemiaCanadian Journal of Physiology and Pharmacology, 1991